The Radient senior management and board of directors have extensive experience in building new companies, sales and marketing, manufacturing, process engineering, the pharmaceutical and nutraceutical industries and venture capital.
Executive and Management
Steven Splinter, PhD. - Chief Technology Officer
Dr. Splinter was the founding President of Radient. He is experienced in strategic planning, technical assessment and development of process technologies, business leadership, and engineering project management. Prior to founding Radient, Dr. Splinter served as Director of Chemical & Environmental Processes at BC Research, where he built and managed a team of scientists, engineers and technologists providing contract R&D services to various clients in the area of chemical and biochemical process development. Dr. Splinter is an expert in interfacial phenomena, having earned a Ph.D. in Engineering Science in 1994. He has authored or co-authored numerous scientific publications and patents and has been invited as a speaker at international science conferences. In 2003, Dr. Splinter was awarded a prestigious 5NR Science Award for Leadership in Sustainable Development for his work in advancing MAP(TM).
Dr. Sagar Kadali PhD- Director of Research
Dr. Kadali has over twenty years experience in senior research and management roles with early stage drug companies and natural product extract companies. He has extensive knowledge of the isolation of natural medicinal products and fundamental organic chemistry, having developed numerous processes for the extraction, purification and isolation of pharmaceutical and nutraceutical ingredients from natural sources. Dr. Kadali is also experienced with the management and implementation of Quality Systems and GMP processes.
Board of Directors
Chairman of the Board - Armand Lavoie
Mr. Lavoie is Managing Director of Foragen Technologies Management Inc. Based in Saskatoon, he is responsible for the management of the fund, evaluating and managing investments in companies developing and commercializing advanced agri-food technologies. Prior to joining Foragen, he was with KPMG, a global consultancy firm, specializing in their life sciences practice area. In his role with KPMG, he consulted extensively with agri-life science companies in their start-up, early commercialization and growth phases. Additionally, Mr. Lavoie consulted directly to several of the global agri-life science corporations on critical strategic and operational issues. Mr. Lavoie specializes in bio-processing, nutraceuticals and functional foods. His development expertise includes business plans, performance improvement programs, business transformation models, market assessments, strategic alliances and operational reviews. Mr. Lavoie holds a B. Sc. from the University of Alberta and an MBA from Sherbrooke/London Business School and he is a P. Ag. Mr. Lavoie has lived and worked in Canada, the United Kingdom, and Mexico.
Mike Cabigon
Mr. Cabigon is Managing Partner of Foundation Equity, an Edmonton-based venture capital fund. As Managing Partner, Mike oversees Foundation's short and long-term investment initiatives and actively works with portfolio companies on strategy, marketing, financing and operations. He is currently a Director of Preo Software Inc., DriveAble Assessment Centres Inc., Tal Ltd. Rocketfuel Games Inc. and is a Board Observer of McCoy Corporation.
Prior to Foundation, Mike held senior positions in business development, strategy and operations in the utility and telecommunications industries. Mike holds a B. Comm from the University of Alberta.
Chris Lumb
Chris Lumb, P.Eng., is the Chief Executive Officer of TEC Edmonton. He was appointed to that position in November, 2009. Prior to that Mr. Lumb was the President and CEO of Micralyne Inc. from 1994 to 2009. After graduating from the University of Waterloo with a Bachelor of Applied Science in Chemical Engineering in 1982, Mr. Lumb's career has been centered around leadership of technology companies to ensure they are profitably focused on addressing market needs, and on building long-term commercial success for emerging technologies. Mr. Lumb was involved in all aspects of Micralyne's development, including leading its transition from a university-owned not-for-profit to a privately held commercial company generating long-term revenue growth throughout the company’s history, and delivering profitable net income and return on equity since the company’s inception. He has been directly involved in major business development initiatives that have resulted in the company having long-term relationships in place with market leading customers. In 2009 Micralyne was identified as the world’s largest independent MEMS (micro-electro-mechanical systems) foundry. Prior to Micralyne, Mr. Lumb was employed in several advanced technology organizations, including the Alberta Research Council and Gellman Hayward and Partners. Mr. Lumb also serves on the Board of Directors of CMC Microsystems, the Board of Trustees of the National Institute for Nanotechnology, on the Board of Directors of ACAMP, and on the Board of the MEMS Industry Group (MIG).
Wolfgang Muhs
Dr. Muhs is an experienced executive from the fine chemical industry. He began his career in R&D at Terochem Laboratories which subsequently acquired Raylo Chemicals in Edmonton, Alberta where Wolfgang became Manager of Research and Development. After the acquisition of Raylo Chemicals by Laporte PLC, Dr. Muhs was appointed President of Raylo Chemicals, which had become a leading-edge company specializing in the medium to large-scale custom manufacture of active pharmaceutical ingredients. In 1999, Wolfgang accepted a transfer to Germany to head Laporte’s global Catalysts and Initiators business.
In 2002, Wolfgang returned to Alberta from Germany, becoming involved in venture investing, followed by a stint as VP Custom Manufacturing & Intermediates for Rhodia Pharma Solutions in England, and from 2006 has been Chairman and Acting CEO Innovotech Inc. of Edmonton, a publicly-traded biotechnology firm he helped found while venture investing. Dr. Muhs obtained his undergraduate degree in Chemistry from the Universität Innsbruck in Austria and his PhD in Organic Chemistry from Universität Konstanz in Germany.
Ian Newton
Ian Newton was born and received his education in New Zealand, graduating with science degrees in Botany and Zoology. Following post graduate work he relocated to Canada. Mr. Newton joined Hoffmann-La Roche in 1979, holding a variety of positions including Group Director, Human Nutrition, Canada, and eventually Director of Business Development and Regulatory Affairs, DSM Nutritional Products, USA. Ian was responsible for the development of various nutrients, new ingredients and also directed nutrition public information programs as a resource for health professionals, academics and the media. He has also published on the dietary and nutritional aspects of vitamins, long chain polyunsaturated fatty acids and nutraceuticals in a variety of scientific journals. Now retired from DSM, Ian manages his own consulting business, Ceres Consulting, based in Markham, Ontario Canada, specializing in business and product development in the health and nutrition sector. Ian actively participates in many areas of human nutrition and is a member of the CRN, AOCS, ISSFAL and IFT, and is involved in Advisory and Boards of Directors positions in health oriented companies, and nutrition related institutions.